Targovax granted US Patent for ONCOS-102 in combination with checkpoint inhibitors
Extends patent protection of ONCOS-102 in combination with checkpoint inhibitors into the US Oslo, 9 March 2021: Targovax ASA (OSE: TRVX), a clinical stage immuno-oncology company developing oncolytic viruses to target hard-to-treat solid tumors, today announce that the US Patent Office has granted US Patent no 10,940,203. The patent covers the use of ONCOS-102 in combination with checkpoint inhibitors (CPI). Torbjørn Furuseth, Chief Financial Officer of Targovax, said: "We are delighted that this US patent has been granted, further strengthening Targovax's intellectual property